Clinical Trials Browser

Phase 2 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Pemetrexed × Clear all

NCT06788912 2026-05-26

MK-3475-01E

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07252739 2026-05-26

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT03631784 2025-03-25

KEYNOTE-799

Phase 2 Completed

216 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03664024 2024-08-22

KEYNOTE-782

Phase 2 Completed

118 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04530227 2020-11-13

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Phase 2 Unknown

Parkinson Disease 4, Autosomal Dominant Lewy Body